Certificate Exchange Network gains popularity among retailers, suppliers
ALEXANDRIA, Va. More than ten major retailersv — boasting more than $150 billion in chain drug sales — have joined an online network developed by the National Association of Chain Drug Stores and RollStream to demonstrate compliance with the Consumer Product Safety Improvement Act of 2008.
NACDS and RollStream’s Certificate Exchange Network — which was introduced in late 2009 — follows document-sharing requirements regarding product safety testing certificates on certain consumer products. It is a way for manufacturers and retailers to connect and keep compliant with Consumer Product Safety Commission and CPSIA guidelines through a simple, easy-to-use browser interface in which retailer members can securely download product certificate needed to demonstrate CPSIA compliance within seconds.
“The Certificate Exchange Network can mean the difference between knowing where the most up-to-date certificates are located when they are needed, and not,” said Rick Cognetti, VP retail merchandising at Kinney Drugs. “So working with Kinney Drug trading partners in the network to avoid governmental fines makes perfect sense.”
“Ensuring compliance with all regulatory requirements, particularly those relating to product safety, is critical to our business,” said Nancy Secours, senior director of supply chain operations at Pfizer. “The zero-install and strong usability, of the NACDS-backed solution made selecting the CEN the logical choice for us.”
Tide looking to open dry-cleaners franchises in Ohio, Atlanta markets
CINCINNATI Procter & Gamble’s detergent brand is looking to open franchised dry-cleaning locations for consumers in the Columbus, Ohio, and Atlanta markets.
Agile Pursuits Franchising, a P&G subsidiary, is looking to open Tide Dry Cleaners for the two cities, which would employ 15 to 20 people per location. Tide Dry Cleaners began in 2008, with a pilot of three dry cleaner stores in Kansas City.
P&G’s Agile Pursuits Franchising entered the car wash business in 2007 with P&G’s Mr. Clean brand, and now is the largest full-service U.S. car wash franchise, with 16 locations in Ohio, Georgia and Texas; another seven facilities are under development.
“Entering the franchise and service market is a model we find very attractive, as shown by the Mr. Clean Car Wash operations,” said Jeff Wampler, general manager for Tide Dry Cleaners. “Expanding our interests into the services industry helps us to reach more consumers’ lives with outstanding service we know consumers are looking for and need.”
FDA approves Pompe disease treatment
SILVER SPRING, Md. The Food and Drug Administration has approved a new treatment for a rare genetic disorder that causes muscle weakness, the agency said Tuesday.
The FDA approved Cambridge, Mass.-based Genzyme’s Lumizyme (alglucosidase alfa) for patients aged 8 and older with late-onset Pompe disease, which occurs in 1-in-40,000 to 300,000 births. Pompe disease causes heart and skeletal muscle weakness, leading to respiratory weakness and death from respiratory failure.
The disease results from the body’s genetic inability to make the enzyme alpha-glucosidase, also known as GAA, which is required for proper muscle functioning. The enzyme is needed to convert the sugar glycogen into energy; without the enzyme, glycogen builds up in the muscle cells, leading to weakness.
The drug is believed to work by replacing deficient GAA and reducing accumulated glycogen in the cells. Currently, the only other treatment available for Pompe disease is Myozyme (alglucosidase alfa), also made by Genzyme. Myozyme has lately been in short supply due to limited manufacturing capacity at Genzyme’s plants in Framingham and Allston Landing, Mass.
“Pompe disease is a devastating condition without the appropriate treatment,” said Julie Beitz, FDA Center for Drug Evaluation and Research Office of Drug Evaluation III director. “The approval of Lumizyme will provide an important treatment for patients diagnosed later in life with Pompe disease.”
The drug is being approved with a risk evaluation and mitigation strategy, or REMS, and will only be available through a restricted distribution system to ensure its use by the correct patient group. The drug will carry a boxed warning to alert patients and physicians to the risk of severe allergic and immune system reactions.